The bone scan index (BSI) is frequently used to quantify bone metastases, evaluate the effectiveness of treatment, and forecast prognosis in prostate cancer. However, bone scintigraphy utilizing Tc-99m-methylene diphosphonate is the sole method supported by the BONE NAVI, which calculates BSI. Researchers created the VSBONER BSI, which uses Tc-99m-hydroxymethylene diphosphonate (HMDP) to compute BSI from bone scintigraphy. For a study, they sought to show that, similar to BONE NAVI, the BSI computed by VSBONER BSI and hot spots (HS), which showed the number of aberrant accumulations, was helpful prognostic markers for patients with prostate cancer bone metastases.
They looked at 322 patients who received bone scintigraphy at the institution for prostate cancer bone metastases. Initially, Tc-99m-HMDP was used for bone scintigraphy. The outcome and length of time it took for each case to reach its conclusion were retrospectively assessed. The outcomes were evaluated against the BSI, and HS was computed using the VSBONER BSI.
The HS≤2 group had a considerably longer survival time (P< 0.001) than the HS >2 group when the patients were split into these 2 groups: HS >2 and HS ≤2. Additionally, when split into 2 groups with BSI>0.46 and BSI≤0.46, the BSI≦0.46 group’s survival time was much greater (P<0.001).
Similar to those acquired with BONE NAVI, the BSI and HS produced using VSBONER BSI may be effective as prognostic indicators.
Reference: karger.com/Article/Abstract/522046
